MED Medifast Inc

Price (delayed)

$18.73

Market cap

$204.85M

P/E Ratio

3.02

Dividend/share

$6.59

EPS

$6.21

Enterprise value

$127.95M

Medifast is the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, which offers scientifically developed products, clinically proven plans and the support of Coaches and a ...

Highlights
The company's quick ratio has surged by 116% YoY and by 25% QoQ
The price to earnings (P/E) is 78% less than the 5-year quarterly average of 13.5 and 57% less than the last 4 quarters average of 7.0
MED's net income has shrunk by 52% YoY and by 32% QoQ
The EPS has dropped by 52% year-on-year and by 32% since the previous quarter

Key stats

What are the main financial stats of MED
Market
Shares outstanding
10.94M
Market cap
$204.85M
Enterprise value
$127.95M
Valuations
Price to book (P/B)
0.97
Price to sales (P/S)
0.23
EV/EBIT
1.54
EV/EBITDA
1.27
EV/Sales
0.14
Earnings
Revenue
$897.81M
EBIT
$83.16M
EBITDA
$100.9M
Free cash flow
$84.67M
Per share
EPS
$6.21
Free cash flow per share
$7.76
Book value per share
$19.36
Revenue per share
$82.3
TBVPS
$27.75
Balance sheet
Total assets
$302.76M
Total liabilities
$91.8M
Debt
$20.57M
Equity
$210.96M
Working capital
$142.4M
Liquidity
Debt to equity
0.1
Current ratio
2.84
Quick ratio
2.03
Net debt/EBITDA
-0.76
Margins
EBITDA margin
11.2%
Gross margin
73.2%
Net margin
7.5%
Operating margin
9%
Efficiency
Return on assets
21.7%
Return on equity
34.3%
Return on invested capital
67.4%
Return on capital employed
36.9%
Return on sales
9.3%
Dividend
Dividend yield
35.18%
DPS
$6.59
Payout ratio
106.1%

MED stock price

How has the Medifast stock price performed over time
Intraday
-0.9%
1 week
-2.45%
1 month
-6.49%
1 year
-80.04%
YTD
-72.14%
QTD
-14.16%

Financial performance

How have Medifast's revenue and profit performed over time
Revenue
$897.81M
Gross profit
$656.75M
Operating income
$80.83M
Net income
$67.76M
Gross margin
73.2%
Net margin
7.5%
The operating income has shrunk by 56% YoY and by 36% QoQ
MED's net income has shrunk by 52% YoY and by 32% QoQ
MED's revenue is down by 41% year-on-year and by 16% since the previous quarter
Medifast's gross profit has decreased by 39% YoY and by 15% from the previous quarter

Growth

What is Medifast's growth rate over time

Valuation

What is Medifast stock price valuation
P/E
3.02
P/B
0.97
P/S
0.23
EV/EBIT
1.54
EV/EBITDA
1.27
EV/Sales
0.14
The price to earnings (P/E) is 78% less than the 5-year quarterly average of 13.5 and 57% less than the last 4 quarters average of 7.0
The EPS has dropped by 52% year-on-year and by 32% since the previous quarter
MED's P/B is 90% below its 5-year quarterly average of 10.0 and 74% below its last 4 quarters average of 3.8
The equity has grown by 23% YoY and by 4.7% from the previous quarter
The P/S is 84% lower than the 5-year quarterly average of 1.4 and 62% lower than the last 4 quarters average of 0.6
MED's revenue is down by 41% year-on-year and by 16% since the previous quarter

Efficiency

How efficient is Medifast business performance
MED's ROE has shrunk by 63% YoY and by 35% QoQ
The return on invested capital has dropped by 56% year-on-year and by 42% since the previous quarter
The ROA has plunged by 50% YoY and by 31% from the previous quarter
The return on sales has declined by 23% year-on-year and by 21% since the previous quarter

Dividends

What is MED's dividend history
DPS
$6.59
Dividend yield
35.18%
Payout ratio
106.1%
Recent dividends

Financial health

How did Medifast financials performed over time
The company's quick ratio has surged by 116% YoY and by 25% QoQ
MED's current ratio has soared by 62% year-on-year and by 17% since the previous quarter
Medifast's debt is 90% less than its equity
Medifast's debt to equity has decreased by 29% YoY and by 9% from the previous quarter
The equity has grown by 23% YoY and by 4.7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.